This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Factors to Impact Innovative Industrial's (IIPR) Q1 Earnings
by Zacks Equity Research
With the cannabis industry gaining prominence, Innovative Industrial's (IIPR) investments in such properties are likely to have aided its Q1 performance, though high expenses might have played a spoilsport.
What's in Store for Gladstone Commercial (GOOD) in Q1 Earnings?
by Zacks Equity Research
Gladstone Commercial's (GOOD) Q1 results are likely to reflect the benefits of its premium facilities at strategic locations and expansion efforts, though high supply might partly limit the growth tempo
What's in the Offing for Realty Income (O) in Q1 Earnings?
by Zacks Equity Research
Healthy demand for Realty Income's (O) properties and a diverse tenant base are likely to have benefited the company's Q1 earnings, though higher interest expenses might have been a dampener.
What's in Store for Simon Property (SPG) This Earnings Season?
by Zacks Equity Research
While Simon Property (SPG) is poised to benefit from its efforts to support omnichannel retailing and solid balance sheet strength, high interest rates are likely to have acted as a spoilsport.
How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Why the Market Dipped But Medical Properties (MPW) Gained Today
by Zacks Equity Research
Medical Properties (MPW) reachead $4.63 at the closing of the latest trading day, reflecting a +0.65% change compared to its last close.
VICI Properties Inc. (VICI) Q1 FFO Match Estimates
by Zacks Equity Research
VICI Properties (VICI) delivered FFO and revenue surprises of 0% and 0.98%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Vornado (VNO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Healthy demand for Vornado's (VNO) premium office assets is likely to have benefited its Q1 performance. However, higher interest expenses are anticipated to have hurt it.
Regency Centers (REG) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Healthy demand for Regency Centers' (REG) shopping centers and strategic acquisitions are likely to have benefited the company's Q1 earnings. However, higher interest rates might have ailed.
What's in Store for Federal Realty (FRT) This Earnings Season?
by Zacks Equity Research
Federal Realty's (FRT) first-quarter results are likely to gain from the healthy leasing activity, though tenant bankruptcies and higher interest expenses act as dampeners.
Digital Realty (DLR) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Solid data center demand and acceleration in digital transformation strategies are likely to have aided Digital Realty's (DLR) Q1 earnings. However, high interest expenses may have ailed.
What's in the Cards for Kimco (KIM) This Earnings Season?
by Zacks Equity Research
While a healthy retail real estate market and focus on developing mixed-use assets are likely to have aided Kimco's (KIM) Q1 earnings, higher interest expenses may have hurt it.
Wall Street's Insights Into Key Metrics Ahead of Medical Properties (MPW) Q1 Earnings
by Zacks Equity Research
Get a deeper insight into the potential performance of Medical Properties (MPW) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Medical Properties (MPW) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw Medical Properties (MPW) settling at $4.09, representing a -0.49% change from its previous close.
Medical Properties (MPW) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
The latest trading day saw Medical Properties (MPW) settling at $4.25, representing a -1.39% change from its previous close.
Medical Properties (MPW) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
In the latest trading session, Medical Properties (MPW) closed at $4.70, marking a -0.42% move from the previous day.
Medical Properties (MPW) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Medical Properties (MPW) stood at $4.26, denoting a +0.24% change from the preceding trading day.
Investors Heavily Search Medical Properties Trust, Inc. (MPW): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Medical Properties Trust (MPW) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Medical Properties (MPW) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Medical Properties (MPW) stood at $4.19, denoting a +0.24% change from the preceding trading day.
Here is What to Know Beyond Why Medical Properties Trust, Inc. (MPW) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Medical Properties (MPW) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Medical Properties (MPW) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Medical Properties (MPW) closed at $4.43 in the latest trading session, marking a +0.91% move from the prior day.
Why the Market Dipped But Medical Properties (MPW) Gained Today
by Zacks Equity Research
In the latest trading session, Medical Properties (MPW) closed at $4.39, marking a +0.23% move from the previous day.
Medical Properties (MPW) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Medical Properties (MPW) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Medical Properties (MPW) Beats Q4 FFO Estimates
by Zacks Equity Research
Medical Properties (MPW) delivered FFO and revenue surprises of 33.33% and 142.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Medical Properties (MPW) in Q4 Earnings?
by Zacks Equity Research
Medical Properties' (MPW) Q4 earnings are likely to have been affected by the high interest rate environment and exposure to certain troubled operators.